#Osteoarthritic Pain Management Treatment Market demand

[shivt123]

Osteoarthritic Pain Management Treatment Market – Industry Trends and Forecast to 2029

[rohans18]

Perilymph Fistula Treatment Market Trends, Share, Competitive Dynamics, Demand - Forecast 2028

Global Perilymph Fistula Treatment Market, By Symptoms (Hearing loss, Vertigo, Tinnitus, Ear Pressure), Causes (Head Trauma, Barotrauma), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Perilymph Fistula Treatment marketing report. The report has a lot to offer to both established and new players in the Perilymph Fistula Treatment industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Perilymph Fistula Treatment market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the perilymph fistula treatment market report are Medtronic, Gem srl, biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Bristol-Myers Squibb Company, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, AstraZeneca; Pfizer Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, ALLERGAN and Aurobindo Pharma among other domestic and global players. Osteoarthritic pain management treatment share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-perilymph-fistula-treatment-market

With the help of credible Perilymph Fistula Treatment market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Perilymph Fistula Treatment market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Perilymph Fistula Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:�� Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[your-dietician]

Bone Therapeutics announces topline results from Phase III

New Post has been published on https://depression-md.com/bone-therapeutics-announces-topline-results-from-phase-iii/

Bone Therapeutics announces topline results from Phase III

REGULATED INFORMATION

No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile similar to placebo and comparator

Prime focus on the continued development and expansion of its mesenchymal stromal cell based allogeneic cell and gene therapy platform

Management to host conference call today at 4pm CEST / 10am EST – details provided below

Gosselies, Belgium, 30 August 2021, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004 did not meet the primary and consequently the key secondary endpoints.

The primary objective of the JTA-004 Phase III study was to demonstrate the efficacy of JTA-004 in reducing osteoarthritic knee pain compared to placebo as measured by the WOMAC® pain subscale three months after treatment. A key secondary objective was the comparison between JTA-004 and comparator Hylan G-F 20 in knee pain relief at month 3. Despite JTA-004’s favorable safety profile, the study did not achieve its main objectives as no statistically significant difference in pain reduction could be observed between any of the treatment, placebo and comparator groups, with all treatment arms showing similar efficacy.

A statistically significant difference in favor of JTA-004 and the active comparator versus placebo was seen in a post-hoc analysis in a subset of patients with higher pain scores at entry.

The Company, in collaboration with existing and potential partners, will consider the options for the future of JTA-004 development.

“The execution of the study was flawless and a good safety profile was observed in line with previous results. These JTA-004 efficacy results are disappointing. Knee osteoarthritis studies are recognized across the industry to be challenging to evaluate. They are also frequently complicated by a high placebo effect. We will continue to analyze the data and will consider potential next steps,” said Miguel Forte, Chief Executive Officer of Bone Therapeutics. “We are now fully committed to the clinical development of our advanced MSC allogeneic cell and gene therapy platform. Bone Therapeutics is concentrating on the development of this platform for the large market of orthopedic indications, with ALLOB. The progress with this platform has enabled us to expand it to other indications, including immunomodulation.”

Bone Therapeutics is focused on the development of its core assets, the allogeneic cell therapy platform, including ALLOB. ALLOB is currently being evaluated in a randomized, double-blind, placebo-controlled Phase IIb study in 178 patients with fresh tibial fractures at risk of delayed or non-union. 5% to 10% of complicated long bone fractures evolve to delayed union and non-union. This study will assess the potential for a single percutaneous injection of ALLOB to accelerate fracture healing and prevent late-stage complications in these patients. Recruitment is expected to be completed in the first half of 2022 and topline results by the end of 2022. Should the pandemic continue, Bone Therapeutics may have to re-evaluate these timelines and, in that eventuality, will communicate again to the market.

Bone Therapeutics is intensifying its efforts to expand its preclinical and clinical pipeline with additional indications by enhancing and “professionalizing” the therapeutic capacity of its cell and gene therapy platform. This includes the development of a next generation of genetically engineered mesenchymal stromal cells (MSC) and the use of highly scalable and versatile cell sources such as induced pluripotent stem cells (iPSC).

Conference call

The management of Bone Therapeutics will host a conference call today at 4:00 pm CEST / 10:00 am EST. To participate in the conference call, please select your dial-in number from the list below quoting the conference ID 825 1002 3115#:

Belgium:  +32 2 290 9360 France:  +33 1 7095 0103 United Kingdom:  +44 208 080 6592 United States:  +1 646 876 9923

About JTA-004 and Phase III knee osteoarthritis study

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable for the treatment of osteoarthritic pain in the knee. It consists of a unique mix of hyaluronic acid – a natural component of knee synovial fluid, plasma proteins, and a fast-acting analgesic. JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain.

The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It evaluates the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee, compared to placebo or Hylan G-F 20, the leading osteoarthritis treatment on the market. The study is being conducted in 22 centers across six European countries as well as Hong Kong. More than 700 patients with mild to moderate symptomatic knee osteoarthritis were treated in this study.

About Knee Osteoarthritis

Osteoarthritis (OA), also known as degenerative joint disease, is the most common chronic joint condition in which the protective cartilage in the joints progressively break down resulting in joint pain, swelling, stiffness and limited range of motion. The knee is one of the joints that are mostly affected by osteoarthritis, with an estimated 250 million cases worldwide.

The prevalence of knee osteoarthritis (KOA) is expected to increase in the coming years due to increasingly aging and obese population. Currently, there is no cure for KOA and treatments focus on relieving and controlling pain and symptoms, preventing disease progression, minimizing disability, and improving quality of life. Most drugs prescribed to KOA patients are topical or oral analgesics and anti-inflammatory drugs. Ultimately, severe KOA leads to highly invasive surgical interventions such as total knee replacement.

About Bone Therapeutics

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a diversified portfolio of cell therapies at different stages ranging from pre-clinical programs in immunomodulation to mid stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company has initiated patient recruitment for the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com.

For further information, please contact:

Bone Therapeutics SA Miguel Forte, MD, PhD, Chief Executive Officer Jean-Luc Vandebroek, Chief Financial Officer Tel: +32 (0)71 12 10 00 investorrelations@bonetherapeutics.com

For Belgian Media and Investor Enquiries: Bepublic Catherine Haquenne Tel: +32 (0)497 75 63 56 catherine@bepublic.be

International Media Enquiries: Image Box Communications Neil Hunter / Michelle Boxall Tel: +44 (0)20 8943 4685 neil.hunter@ibcomms.agency / michelle@ibcomms.agency

For French Media and Investor Enquiries: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier and Arthur Rouillé Tel: +33 (0)1 44 71 94 94 bone@newcap.eu

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Source link

[dbmrmarketresearchnews]

Osteoarthritic Pain Management Treatment Market is estimated to grow at a healthy growth rate for 2020-2027 with factors such as no permanent treatment available in the market, low per capita income in the developing countries among others restraining the market.

[data-bridge-market-research]

Market Analysis: Global Osteoarthritic Pain Management Treatment Market

Increase in the number of cases of Osteoarthritis is the rise in the geriatric population all over the world. This has left the industry with plenty of room to grow, because of the fact that there are no particular treatments available in the markets that are effective.

Market Definition: Global Osteoarthritic Pain Management Treatment Market

Osteoarthritis is a type of joint disorder that attacks the cartilage in between the bones and makes the joints swell up, red in color and making difficult for the joints to move properly. The usual symptoms of it are swelling, decrease in range of motion, and immobility in arms and legs specially when the spine is affected with osteoarthritis. All of the usual daily activities are affected.

Market Drivers

The government awareness programs about the disease has been considered a major factor in the improvement of the treatment market for Osteoarthritis

Increased knowledge and awareness amongst the people is causing the demand for the treatment to soar high, in turn increasing the growth of the industry

Increased healthcare affordability in the US will drive the market growth upwards as it makes the treatment accessible for the affected population

Market Restraints

Due to no permanent treatment available in the market, the industry is set to experience a restrictive market growth

Medicines or treatments are only available as of yet, to make the symptoms manageable and not the complete solution for the disease

Low per capita income in the still developing countries will be one of the major factors restricting the growth of the industry

Market Segmentation: Global Osteoarthritic Pain Management Treatment Market

Type

Diagnosis (Imaging)

Treatment

End-Users

Region

Hip

Wrist

Spinal

Finger Joints

Magnetic Resonance Imaging (MRI)

X-Rays

Medication (Analgesics, Non-Steroidal)

Surgery

Therapy

Hospitals

Clinics

Medical Institutes

Research Institutes

North America (US, Canada, Mexico)

Europe (Germany, UK, Italy, France, Spain)

Asia Pacific (China, India, Japan, Singapore, Australia, New Zealand)

South America (Brazil, Chile, Uruguay, Argentina)

Middle East & Africa (UAE, Saudi Arabia, South Africa, Qatar)

Key Developments in the Market: Global Osteoarthritic Pain Management Treatment Market

In September 2016, Pfizer Inc. captured the Medivation Inc. that is focused on the development of innovative therapies to the diseases that have only limited treatment options available in the market.

In December 2016, Pfizer also acquired the commercialization and development rights from AstraZeneca regarding the late-stage small molecule business, which will help in the regeneration of cartilage found ruptured or disrupted in Osteoarthritis

Competitive Analysis: Global Osteoarthritic Pain Management Treatment Market

The Global Osteoarthritic Pain Management Treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Osteoarthritic Pain Management Treatment market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Osteoarthritic Pain Management Treatment Market

Pfizer Inc., AstraZeneca, Medivation Inc., Eli Lilly and Company, Abiogen Pharma S.p.A., Merck Sharp & Dohme Corp., Novartis AG, GlaxoSmithKline plc., Zimmer Biomet, Abbott Laboratories, Johnson & Johnson Services, Kolon TissueGene Inc., Ampio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma, BioDelivery Sciences International LLC., Crystal Genomics, Daiichi-Sankyo Company Limited,  Endo Pharmaceuticals Inc., among others are the major Market players.

Research Methodology: Global Osteoarthritic Pain Management Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Technological Writers, and Investors among others.

Supply Side: Product Managers, Marketing Managers, Distributors, Market Intelligence committees, Regulatory Authorities, Medical Institutes

Reasons to Purchase this Report

The report offers deep insights into the working structure of the market mechanisms and market segmentation

The report offers up the information on the different segments available in the market in this sector and the highest expected CAGR accordingly

Focuses on the market drivers and restraints and the growth factors associated with it

Customization of the Report

All segmentation provided above in this report is represented at country level.

All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)